• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » TransMedics down on missed Q4 projections

TransMedics down on missed Q4 projections

March 3, 2020 By Sean Whooley

(Image from TransMedics)

TransMedics (NSDQ:TMDX) shares dipped today on fourth-quarter results that came up short of the consensus forecast.

The Andover, Mass.–based company posted losses of -$9.2 million, or -43¢ per share, on sales of $6.1 million for the three months ended Dec. 31, 2019, for a 20.2% bottom-line slide on sales growth of 70.9%.

Adjusted to exclude one-time items, losses per share were also -43¢, 4¢ behind Wall Street’s projections. TransMedics attributed some additional operating expenses due to higher SG&A costs stemming from commercial investments and the costs associated with being a public company. Other clinical trials and R&D expenses drove costs even higher, as well.

“2019 was a momentum-building year for Transmedics in which we built a solid foundation for growth and made meaningful progress across our three OCS products,” TransMedics president & CEO Dr. Waleed Hassanein said in a news release. “Through 2020 and beyond, we look forward to building on this momentum to catalyze our growth with accelerated commercial traction and the continued advancement of our clinical programs.”

The company did not offer guidance for its 2020 EPS, but said it anticipates revenue to be in the range of $40 million to $43 million over the course of the year, representing growth between 69% and 82%, compared to 2019.

TransMedics developed a transportation system for organ transplants that’s designed to keep donated hearts, lungs and livers in near-living condition until transplantation.

Shares of TMDX were down -2.6% at $14.57 per share in mid-morning trading today.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Transplants, Wall Street Beat Tagged With: transmedics

More recent news

  • Mount Sinai adopts Flosonics wearable ultrasound device
  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy